Impact of interleukin-28B genotype on in vitro and in vivo systems of hepatitis C virus replication

Hepatology Research

Volumn 42, Issue 9, 2012, Pages 841-853

  Chayama, Kazuaki ^a,b,c   Hayes, C Nelson ^a,b,c   Imamura, Michio ^a,b,c  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c RIKEN   (Japan)

Author keywords

interferon; Cell culture; Chimeric mouse; Interferon stimulated genes; Single nucleotide polymorphism

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN;

ADAPTIVE IMMUNITY; AMINO ACID SUBSTITUTION; CELL TYPE; CHIMERA; DRUG EFFICACY; ERADICATION THERAPY; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

EID: 84865146193     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.01002.x     Document Type: Review

References (69)

1. Ank N, Iversen MB, Bartholdy C etal. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 2008; 180: 2474-85.
2. Bartlett NW, Buttigieg K, Kotenko SV, Smith GL. Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J Gen Virol 2005; 86: 1589-96.
3. Brand S, Beigel F, Olszak T etal. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 2005; 289: G960-8.
4. Doyle SE, Schreckhise H, Khuu-Duong K etal. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006; 44: 896-906.
5. Fox BA, Sheppard PO, O'Hara PJ. The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-lambda family. PLoS ONE 2009; 4: e4933.
6. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 2005; 31: 109-18.
7. Sheppard P, Kindsvogel W, Xu W etal. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-8.
8. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
9. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
10. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
11. Rauch A, Kutalik Z, Descombes P etal. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-45. 45 e1-7.
12. Ochi H, Maekawa T, Abe H etal. IL-28B predicts response to chronic hepatitis C therapy -fine-mapping and replication study in Asian populations. J Gen Virol 2011; 92: 1071-81.
13. Moghaddam A, Melum E, Reinton N etal. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011; 53: 746-54.
14. Sakamoto N, Nakagawa M, Tanaka Y etal. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J Med Virol 2011; 83: 871-8.
15. Yu ML, Huang CF, Huang JF etal. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011; 53: 7-13.
16. Scherzer TM, Hofer H, Staettermayer AF etal. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol 2011; 54: 866-71.
17. Kawaoka T, Hayes CN, Ohishi W etal. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol 2011; 54: 408-14.
18. Sarrazin C, Susser S, Doehring A etal. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011; 54: 415-21.
19. Mangia A, Thompson AJ, Santoro R etal. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010; 139: 821-7, 7 e1.
20. Thomas DL, Thio CL, Martin MP etal. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
21. Tillmann HL, Thompson AJ, Patel K etal. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010; 139: 1586-92, 92 e1.
22. Bartenschlager R, Pietschmann T. Efficient hepatitis C virus cell culture system: what a difference the host cell makes. Proc Natl Acad Sci U S A 2005; 102: 9739-40.
23. Wakita T, Pietschmann T, Kato T etal. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-6.
24. Zhong J, Gastaminza P, Cheng G etal. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005; 102: 9294-9.
25. Sumpter R, Jr, Loo YM, Foy E etal. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005; 79: 2689-99.
26. Pileri P, Uematsu Y, Campagnoli S etal. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-41.
27. Durantel D, Zoulim F. Going towards more relevant cell culture models to study the in vitro replication of serum-derived hepatitis C virus and virus/host cell interactions? J Hepatol 2007; 46: 1-5.
28. Ploss A, Khetani SR, Jones CT etal. Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc Natl Acad Sci U S A 2010; 107: 3141-5.
29. Narbus CM, Israelow B, Sourisseau M etal. HepG2 cells expressing MicroRNA miR-122 support the entire hepatitis C virus life cycle. J Virol 2011; 85: 12087-92.
30. Kotenko SV, Gallagher G, Baurin VV etal. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77.
31. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol 2004; 76: 314-21.
32. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 2004; 279: 32269-74.
33. Brand S, Zitzmann K, Dambacher J etal. SOCS-1 inhibits expression of the antiviral proteins 2′, 5′-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. Biochem Biophys Res Commun 2005; 331: 543-8.
34. Siren J, Pirhonen J, Julkunen I, Matikainen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol 2005; 174: 1932-7.
35. Mennechet FJ, Uze G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006; 107: 4417-23.
36. Maher SG, Sheikh F, Scarzello AJ etal. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 2008; 7: 1109-15.
37. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008; 4: e1000017.
38. Zitzmann K, Brand S, Baehs S etal. Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem Biophys Res Commun 2006; 344: 1334-41.
39. Lasfar A, Lewis-Antes A, Smirnov SV etal. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 2006; 66: 4468-77.
40. Numasaki M, Tagawa M, Iwata F etal. IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol 2007; 178: 5086-98.
41. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T. Antitumor activity of IFN-lambda in murine tumor models. J Immunol 2006; 176: 7686-94.
42. Wongthida P, Diaz RM, Galivo F etal. Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res 2010; 70: 4539-49.
43. Yoshimoto K, Kishida T, Nakano H etal. Interleukin-28B acts synergistically with cisplatin tosuppress the growth of head and neck squamous cell carcinoma. J Immunother 2011; 34: 139-48.
44. Bensadoun P, Rodriguez C, Soulier A, Higgs M, Chevaliez S, Pawlotsky JM. Genetic background of hepatocyte cell lines: are in vitro hepatitis C virus research data reliable? Hepatology 2011; 54: 748.
45. Mercer DF, Schiller DE, Elliott JF etal. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-33.
46. Tateno C, Yoshizane Y, Saito N etal. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004; 165: 901-12.
47. Vanwolleghem T, Libbrecht L, Hansen BE etal. Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. J Hepatol 2010; 53: 468-76.
48. Kimura T, Imamura M, Hiraga N etal. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice. J Gen Virol 2008; 89: 2108-13.
49. Hiraga A, Cohen P. Phosphorylation of the glycogen-binding subunit of protein phosphatase-1G by cyclic-AMP-dependent protein kinase promotes translocation of the phosphatase from glycogen to cytosol in rabbit skeletal muscle. Eur J Biochem 1986; 161: 763-9.
50. Suda G, Sakamoto N, Itsui Y etal. IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones. Virology 2010; 407: 80-90.
51. Steenbergen RH, Joyce MA, Lund G etal. Lipoprotein profiles in SCID/uPA mice transplanted with human hepatocytes become human-like and correlate with HCV infection success. Am J Physiol Gastrointest Liver Physiol 2010; 299: G844-54.
52. Gal-Tanamy M, Keck ZY, Yi M etal. In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A 2008; 105: 19450-5.
53. Law M, Maruyama T, Lewis J etal. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008; 14: 25-7.
54. Hiraga N, Abe H, Imamura M etal. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatology 2011; 54: 764-71.
55. Abe H, Ochi H, Maekawa T etal. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 2010; 53: 439-43.
56. Urban TJ, Thompson AJ, Bradrick SS etal. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52: 1888-96.
57. Honda M, Sakai A, Yamashita T etal. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509.
58. Sarasin-Filipowicz M, Oakeley EJ, Duong FH etal. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105: 7034-9.
59. Shebl FM, Maeder D, Shao Y, Prokunina-Olsson L, Schadt EE, O'Brien TR. In the absence of HCV infection, interferon stimulated gene expression in liver is not associated with IL28B genotype. Gastroenterology 2010; 139: 1422-4.
60. Lindh M, Lagging M, Norkrans G, Hellstrand K. A model explaining the correlations between IL28B-related genotypes, hepatitis C virus genotypes, and viral RNA levels. Gastroenterology 2010; 139: 1794-6.
61. Taniguchi T, Takaoka A. A weak signal for strong responses: interferon-alpha/beta revisited. Nat Rev Mol Cell Biol 2001; 2: 378-86.
62. Dill MT, Duong FH, Vogt JE etal. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140: 1021-31 e10.
63. Asahina Y, Tsuchiya K, Muraoka M etal. Association of gene expression involving innate immunity and genetic variation in IL28B with antiviral response. Hepatology 2011; 55: 20-9.
64. Akuta N, Suzuki F, Kawamura Y etal. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-10.
65. Akuta N, Suzuki F, Sezaki H etal. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2006; 78: 83-90.
66. Hayes CN, Kobayashi M, Akuta N etal. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 2011; 60: 261-7.
67. Tachi Y, Katano Y, Honda T etal. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. Liver Int 2010; 30: 554-9.
68. Aly HH, Oshiumi H, Shime H etal. Development of mouse hepatocyte lines permissive for hepatitis C virus (HCV). PLoS ONE 2011; 6: e21284.
69. Marcello T, Grakoui A, Barba-Spaeth G etal. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-98.